longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

13152

13152
----

LongbridgeAI

Hong Kong Midday: Hang Seng up 1.14%; mRNA stocks explode as Everest Medicines soars 68%

Market Pulse
Aug 20, 2026 at 04:21 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Moderna's cancer vaccine breakthrough ignites mRNA sector, Everest Medicines surges 68%, while Kuaishou tumbles nearly 10% post-earnings.

Hong Kong's three major indices closed higher at midday on August 20. The Hang Seng Index rose 291.25 points or 1.14% to 25,786.32; the Hang Seng China Enterprises Index gained 1.42% to 8,591.65; and the Hang Seng Tech Index advanced 1.54% to 4,754.13. Half-day turnover reached approximately HK$144.1 billion.

On the market front, Moderna's cancer vaccine breakthrough ignited the mRNA sector, with the Hang Seng Innovative Drug Index skyrocketing over 8%. Everest Medicines soared over 68%, CanSino Biologics surged more than 51%, and 3D Medicines at one point spiked 130%. New energy vehicle stocks broadly advanced on rural adoption policy support, with Li Auto jumping nearly 6%. Major tech names also firmed, with Xiaomi climbing close to 4%. On the flip side, Kuaishou tumbled nearly 10% after its earnings release.

mRNA stocks erupt: Everest Medicines +68%, CanSino +51%

At the midday break, Everest Medicines (01952.HK) surged over 68% to HK$40.00; CanSino Biologics (06185.HK) soared more than 51% to HK$35.32; 3D Medicines (01244.HK) rallied over 55% to HK$3.39, having spiked as much as 130% intraday; and Genscript Biotech (01548.HK) gained nearly 15%. The Hang Seng Innovative Drug Index surged over 8%, while the Hang Seng Biotech Index jumped nearly 7%. The catalyst: Moderna reported a breakthrough with its mRNA cancer vaccine, which demonstrated significant efficacy in clinical trials, triggering a broad-based rally across Hong Kong's innovative drug sector.

Kuaishou tumbles nearly 10% post-earnings on broker downgrades

By midday, Kuaishou (01024.HK) slumped nearly 10% to HK$34.12, with half-day turnover exceeding HK$5.8 billion. The short-video platform reported Q2 adjusted net profit of RMB3.913 billion, down 30.3% year-on-year. Daiwa downgraded the stock to Hold and slashed its target price from HK$72 to HK$40, while Morgan Stanley and Citi also lowered their ratings.

Among major tech names, Xiaomi Corp (01810.HK) rose nearly 4% to HK$28.44 after Q2 revenue reached RMB108.9 billion, beating expectations. Baidu (09888.HK) gained over 3%. In the new energy vehicle space, Li Auto (02015.HK) climbed nearly 6% after nine government departments including the Ministry of Commerce issued policies to support new energy vehicle adoption in rural areas. Elsewhere, Kingsoft Cloud (03896.HK) jumped nearly 9% as Q2 revenue hit a record high of RMB3.07 billion. Yixin Group (02858.HK) advanced nearly 11% after interim profit rose 28%. Zhaojin Mining Industry (01818.HK) surged over 8%.

Login to unlock2,007characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

EVEREST MED

EVEREST MED

HK01952

-8.52%

CANSINOBIO

CANSINOBIO

HK06185

-6.35%

3D MEDICINES

3D MEDICINES

HK01244

0.00%